Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines
| Autor: | Sang-Cheol, Lee, Hee-Jeong, Cheong, Sook-Ja, Kim, Jina, Yoon, Han Jo, Kim, Kyoung Ha, Kim, Se Hyoung, Kim, Hyun Jung, Kim, Sang Byung, Bae, Chan-Kyu, Kim, Namsu, Lee, Kyu Taeg, Lee, Sung Kyu, Park, Dae Sik, Hong, Hee Sook, Park, Jong-Ho, Won |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Indoles
Dose-Response Relationship Drug Acetylation Apoptosis Receptors Death Domain HCT116 Cells Hydroxamic Acids Umbilical Cord Enzyme Activation Histones TNF-Related Apoptosis-Inducing Ligand Drug Resistance Neoplasm Caspases Antineoplastic Combined Chemotherapy Protocols Colonic Neoplasms Panobinostat Leukocytes Mononuclear Humans Apoptosis Regulatory Proteins HT29 Cells Cell Proliferation |
| Zdroj: | Anticancer research. 31(10) |
| ISSN: | 1791-7530 |
| Popis: | Despite the considerable advances in the treatment of colorectal cancer, substantial changes in treatment strategies are required to overcome the problems of drug resistance and toxicity.Combinations of Pan-deacetylase inhibitor LBH589 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were studied in three colon cancer cell lines, HCT116, colo205, and HT29 (HCT116 and colo205 are TRAIL sensitive, whereas HT29 is TRAIL resistant).It was found that TRAIL-induced cytotoxicity was enhanced by LBH589 cotreatment in the TRAIL-sensitive cell lines, and in the TRAIL-resistant HT29 cell line. The cytotoxicity of low-dose TRAIL plus LBH589 was found to be comparable to that of high-dose TRAIL plus LBH589. Additionally, TRAIL and LBH589 were significantly less toxic to normal UCB mononuclear cells than to the three colon cancer cell lines examined.LBH589 enhances TRAIL-induced apoptosis in human colon cancer cell lines, especially those resistant to TRAIL-induced apoptosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|